Health Care • Biotechnology: Pharmaceutical Preparations
$65.93 ▲ +1.11
(+1.71%)
MKT CAP: $37.91B • VOL: 2.45M
52W L $36 52W H $68
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$55
MEDIAN
$74
MEAN
$75
HIGH
$90
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RPRX TAPE
RPRX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $79.78 | $75.82 | 2025-02-14 | $60.00 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $83.07 | $77.80 | 2025-02-06 | $61.97 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $75.16 | $72.52 | 2025-01-29 | $63.29 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $67.25 | — | 2025-01-17 | $64.61 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $58.02 | $62.63 | 2025-01-09 | $58.68 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $78.46 | $68.57 | 2024-12-18 | $57.36 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $63.95 | $66.59 | 2024-12-04 | $61.31 | -4.3% | 48% | C |